Previcox

Country: European Union

Language: Maltese

Source: EMA (European Medicines Agency)

Active ingredient:

firocoxib

Available from:

Boehringer Ingelheim Vetmedica GmbH

ATC code:

QM01AH90

INN (International Name):

firocoxib

Therapeutic group:

Klieb

Therapeutic area:

Anti-inflammatory and anti-rheumatic products, non-steroids

Therapeutic indications:

TabletsFor-serħan mill-uġigħ u l-infjammazzjoni assoċjati ma ' l-ostjoartrite fil-klieb. Għall-eżenzjoni ta 'uġigħ u infjammazzjoni wara l-operazzjoni assoċjati ma' tessut artab, kirurġija ortopedika u dentali fil-klieb. Orali pasteAlleviation ta 'l-uġigħ u l-infjammazzjoni assoċjati ma' l-ostjoartrite u għat-tnaqqis tat-tizpip assoċjat fiż-żwiemel.

Product summary:

Revision: 23

Authorization status:

Awtorizzat

Authorization date:

2004-09-13

Patient Information leaflet

                                18
3B
B. FULJETT TA' TAGĦRIF FIL-PAKKETT
19
FULJETT TA’ TAGĦRIF FIL-PAKKETT
PREVICOX 57 MG PILLOLI LI TGĦOMODHOM GĦALL-KLIEB
PREVICOX 227 MG PILLOLI LI TGĦOMODHOM GĦALL-KLIEB
1.
L-ISEM U L-INDIRIZZ TAS-SID TAL-AWTORIZZAZZJONI TAL-KUMMERĊ, U
LISEM U L-INDIRIZZ TAS-SID TAL-AWTORIZZAZZJONI TAL-MANIFATTURA
RESPONSABBLI LI JĦALLI L-KONSENJA TMUR FIS-SUQ , JEKK DIFFERENTI
Sid l-Awtorizzazzjoni tal-Kummerċ:
Boehringer Ingelheim Vetmedica GmbH
55216 Ingelheim/Rhein
IL-ĠERMANJA
Manifattur li jħalli l-konsenja tmur fis-suq:
Boehringer Ingelheim Animal Health France SCS,
4 Chemin du Calquet, 31000 Toulouse, France
2.
ISEM TAL-PRODOTT MEDIĊINALI VETERINARJU
Previcox 57 mg pilloli li tgħomodhom għall-klieb
Previcox 227 mg pilloli li tgħomodhom għall-klieb
firocoxib
3.
DIKJARAZZJONI TAS-SUSTANZA(I) ATTIVA(I) U INGREDJENT(I) OĦRA
Kull pillola li tomgħodha fiha:
SUSTANZA ATTIVA:
firocoxib
57 mg
jew
firocoxib
227 mg
SUSTANZI MHUX ATTIVI:
Iron oxides (E172)
Karamell (E150d)
Pilloli kannella ċari, tondi, konvessi, b’talja fi forma ta’
salib fuq naħa waħda. Il-pilloli jistgħu
jinqasmu f’żewġ jew 4 partijiet ugwali.
4.
INDIKAZZJONI (JIET)
Biex itaffi l-uġigħ u l-infjammazzjoni assoċjati ma’
l-ostjoartrite fil-klieb.
Biex ittaffi l-uġigħ ta’ wara operazzjoni u l-infjammazzjoni
assoċjati ma’ kirurġija tas-
_soft-tissue,_
ta’
l-għadam u tas-snien fil-klieb.
5.
KONTRAINDIKAZZJONIJIET
Tużax fi klieb nisa li huma tqal jew qed jagħtu l-ħalib.
Tużax f’annimali li għandhom anqas minn 10 ġimgħat jew jiżnu
inqas minn 3 kg.
Tużax f’annimali li qed isofru minn emorraġija gastrointestinali,
dyscrasia tad-demm jew f’każijiet
oħra ta’ emorraġija.
20
Tużax flimkien ma kortikosterojdi jew mediċini oħra
anti-infjammatorji mhux sterojdi (NSAIDs).
6.
EFFETTI MHUX MIXTIEQA*
Ġieli ġew irrapportati każi ta’ rimettar u dijarea. Dawn
l-effetti huma ġeneralment ta’ natura transitorja
u huma riversibbli meta titwaqqaf il-kura. Disturbi fil-kliewi u/jew
fil-fwied ġew irrapportati f
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
ANNESS I
0B
KARATTERISTIĊI TAL-PRODOTT FIL-QOSOR
2
1.
ISEM TAL-PRODOTT MEDIĊINALI VETERINARJU
Previcox pilloli ta’ 57 mg li tomgħodhom għall-klieb.
Previcox pilloli ta’ 227 mg li tomgħodhom għall-klieb.
firocoxib
2.
KOMPOŻIZZJONI KWALITATTIVA U KWANTITATTIVA
Kull pillola li tomgħodha fiha:
SUSTANZA ATTIVA:
firocoxib
57 mg
jew
firocoxib
227 mg
SUSTANZI MHUX ATTIVI:
Iron oxides (E172)
Karamell (E150d)
Għal-lista sħiħa ta’ l-ingredjenti (mhux attivi), ara s-sezzjoni
6.1.
3.
GĦAMLA FARMAĊEWTIKA
Pilloli li tomgħodhom.
Pilloli kannella ċari, tondi, konvessi, b’talja fi forma ta’
salib fuq naħa waħda. Il-pilloli jistgħu .
jinqasmu f’żewġ jew 4 partijiet ugwali.
4.
TAGĦRIF KLINIKU
4.1
SPEĊI LI FUQHOM SER JINTUŻA L-PRODOTT
Klieb.
4.2
INDIKAZZJONIJIET GĦAL UŻU TAL-PRODOTT LI JISPEĊIFIKAW L-ISPEĊI LI
FUQHOM SE JINTUŻA L-PRODOTT.
Biex ittaffi l-uġigħ u l-infjammazzjoni assoċjati ma’
l-ostjoartrite fil-klieb.
Biex ittaffi l-uġigħ ta’ wara operazzjoni u l-infjammazzjoni
assoċjati ma’ kirurġija tas-
_soft-tissue, _
ta’
l-għadam u tas-snien fil-klieb.
4.3
KONTRA INDIKAZZJONIJIET
Tużax fi klieb nisa li huma tqal jew qed jagħtu l-ħalib.
Tużax f’annimali li għandhom anqas minn 10 ġimgħat jew li jiżnu
inqas minn 3 kg.
Tużax f’annimali li qed isofru minn emorraġija gastrointestinali,
_dyscrasia_
tad-demm jew f’każijiet
oħra ta’ emorraġija.
Tużax flimkien ma kortikosterojdi jew mediċini oħra
anti-infjammatorji mhux sterojdi (NSAIDs)
4.4
TWISSIJIET SPEĊJALI 
Xejn.
4.5
PREKAWZJONIJIET SPEĊJALI GĦALL-UŻU
Prekawzjonijiet speċjali għall-użu fl-annimali
Id-doża rrikmandata, ara sezzjoni 4.9, m’għandhiex tinqabeż. .
3
L-użu fuq annimali żgħar ħafna, jew fuq annimali b’suspett jew
konferma ta’ nuqqas tal-funzjonijiet
tal-kliewi, qalb, jew fwied jista’ jinvolvi riskju akbar. Jekk dan
l-użu ma jistax jiġi evitat, dawn il-klieb
jeħtieġu monitoraġġ veterinarju b’attenzjoni kbira.
Evit
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 28-04-2020
Summary of Product characteristics Summary of Product characteristics Bulgarian 28-04-2020
Public Assessment Report Public Assessment Report Bulgarian 13-11-2012
Patient Information leaflet Patient Information leaflet Spanish 28-04-2020
Public Assessment Report Public Assessment Report Spanish 13-11-2012
Patient Information leaflet Patient Information leaflet Czech 28-04-2020
Public Assessment Report Public Assessment Report Czech 13-11-2012
Patient Information leaflet Patient Information leaflet Danish 28-04-2020
Public Assessment Report Public Assessment Report Danish 13-11-2012
Patient Information leaflet Patient Information leaflet German 28-04-2020
Public Assessment Report Public Assessment Report German 13-11-2012
Patient Information leaflet Patient Information leaflet Estonian 28-04-2020
Public Assessment Report Public Assessment Report Estonian 13-11-2012
Patient Information leaflet Patient Information leaflet Greek 28-04-2020
Public Assessment Report Public Assessment Report Greek 13-11-2012
Patient Information leaflet Patient Information leaflet English 28-04-2020
Public Assessment Report Public Assessment Report English 13-11-2012
Patient Information leaflet Patient Information leaflet French 28-04-2020
Public Assessment Report Public Assessment Report French 13-11-2012
Patient Information leaflet Patient Information leaflet Italian 28-04-2020
Public Assessment Report Public Assessment Report Italian 13-11-2012
Patient Information leaflet Patient Information leaflet Latvian 28-04-2020
Public Assessment Report Public Assessment Report Latvian 13-11-2012
Patient Information leaflet Patient Information leaflet Lithuanian 28-04-2020
Summary of Product characteristics Summary of Product characteristics Lithuanian 28-04-2020
Public Assessment Report Public Assessment Report Lithuanian 13-11-2012
Patient Information leaflet Patient Information leaflet Hungarian 28-04-2020
Summary of Product characteristics Summary of Product characteristics Hungarian 28-04-2020
Public Assessment Report Public Assessment Report Hungarian 13-11-2012
Patient Information leaflet Patient Information leaflet Dutch 28-04-2020
Public Assessment Report Public Assessment Report Dutch 13-11-2012
Patient Information leaflet Patient Information leaflet Polish 28-04-2020
Public Assessment Report Public Assessment Report Polish 13-11-2012
Patient Information leaflet Patient Information leaflet Portuguese 28-04-2020
Summary of Product characteristics Summary of Product characteristics Portuguese 28-04-2020
Public Assessment Report Public Assessment Report Portuguese 13-11-2012
Patient Information leaflet Patient Information leaflet Romanian 28-04-2020
Public Assessment Report Public Assessment Report Romanian 13-11-2012
Patient Information leaflet Patient Information leaflet Slovak 28-04-2020
Public Assessment Report Public Assessment Report Slovak 13-11-2012
Patient Information leaflet Patient Information leaflet Slovenian 28-04-2020
Summary of Product characteristics Summary of Product characteristics Slovenian 28-04-2020
Public Assessment Report Public Assessment Report Slovenian 13-11-2012
Patient Information leaflet Patient Information leaflet Finnish 28-04-2020
Public Assessment Report Public Assessment Report Finnish 13-11-2012
Patient Information leaflet Patient Information leaflet Swedish 28-04-2020
Public Assessment Report Public Assessment Report Swedish 13-11-2012
Patient Information leaflet Patient Information leaflet Norwegian 28-04-2020
Summary of Product characteristics Summary of Product characteristics Norwegian 28-04-2020
Patient Information leaflet Patient Information leaflet Icelandic 28-04-2020
Summary of Product characteristics Summary of Product characteristics Icelandic 28-04-2020
Patient Information leaflet Patient Information leaflet Croatian 28-04-2020

Search alerts related to this product

View documents history